<DOC>
	<DOCNO>NCT00493220</DOCNO>
	<brief_summary>The objective study : - establish safety subcutaneous administration ceftriaxone different concentration , without HYLENEX recombinant , determine maximum tolerated concentration ; - establish pharmacokinetic comparability subcutaneous administration ceftriaxone HYLENEX recombinant subcutaneous administration without HYLENEX recombinant IV administration .</brief_summary>
	<brief_title>Pharmacokinetic Safety Study HYLENEX Recombinant-Augmented Subcutaneous Ceftriaxone Administration</brief_title>
	<detailed_description />
	<mesh_term>Ceftriaxone</mesh_term>
	<criteria>Male female , 1865 year age If female : nonlactating ; nonpregnant ; incapable become pregnant , take specific precaution avoid become pregnant study Normal clinical laboratory parameter Adequate venous access upper extremity Agreeing refrain smoking ingest alcohol caffeinecontaining product study Good health base medical history , physical examination laboratory test Nonsmoking ; smoke less 10 cigarette per day willing refrain use nicotine product study Received cephalosporin within 21 day prior study anticipated receive nonstudy cephalosporin study Pregnant breastfeeding . Previously exposed hyaluronidase drug product Medical condition present unacceptable safety risk likely prevent completion study Known hypersensitivity hyaluronidase ingredient HYLENEX recombinant Contraindication ceftriaxone , include know allergy betalactam antibiotic Local condition preclude subcutaneous injection injection site evaluation History gastrointestinal disease ( particular colitis ) Consumption caffeine methylxanthinecontaining beverage within 24 hour and/or PK sample period Participation study investigational drug device within 30 day study Serum hemoglobin &lt; 12 g/dL . Blood donation significant loss blood within 56 day , plasma donation within 7 day , prior study Medical history/condition , screen physical examination find clinical laboratory result preclude safe participation study , might adversely effect interpretation study result History drug alcohol abuse within 2 year prior study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>ceftriaxone</keyword>
	<keyword>cephalosporin</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>subcutaneous</keyword>
	<keyword>hyaluronoglucosaminidase</keyword>
	<keyword>hyaluronidase</keyword>
	<keyword>hyaluronan</keyword>
	<keyword>rHuPH20</keyword>
</DOC>